Palatin Technologies Company Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.
The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases.
In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy.
Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials.
Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
| Country | United States |
| Founded | 1986 |
| Industry | Other |
| Employees | 30 |
| CEO | Carl Spana |
Contact Details
Address: Cedar Brook Corporate Center Cranbury, Delaware 08512 United States | |
| Phone | 609 495 2200 |
| Website | palatin.com |
Stock Details
| Ticker Symbol | PTNT |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Carl Spana | Chief Executive Officer |
| Stephen Wills | Chief Financial Officer |
| Stephen Wills | Chief Operating Officer |
| Burns McClellan | Head of Investor Relations |